Vanguard Group Inc. Purchases 141,030 Shares of Artivion, Inc. $AORT

Vanguard Group Inc. grew its position in shares of Artivion, Inc. (NYSE:AORT) by 4.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 3,170,089 shares of the company’s stock after acquiring an additional 141,030 shares during the quarter. Vanguard Group Inc. owned about 0.07% of Artivion worth $144,588,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NBC Securities Inc. purchased a new position in Artivion during the fourth quarter worth $245,000. Arizona State Retirement System raised its stake in shares of Artivion by 4.6% in the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after acquiring an additional 494 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Artivion by 4.9% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 138,558 shares of the company’s stock worth $6,320,000 after acquiring an additional 6,443 shares during the last quarter. Round Rock Advisors LLC boosted its stake in shares of Artivion by 54.5% during the 4th quarter. Round Rock Advisors LLC now owns 13,223 shares of the company’s stock worth $603,000 after purchasing an additional 4,663 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Artivion by 21.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,804 shares of the company’s stock valued at $812,000 after purchasing an additional 3,165 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Artivion

In other news, SVP Marshall S. Stanton sold 2,149 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $81,189.22. Following the transaction, the senior vice president owned 60,097 shares in the company, valued at approximately $2,270,464.66. This trade represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Amy Horton sold 901 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $34,039.78. Following the completion of the sale, the chief accounting officer directly owned 139,088 shares of the company’s stock, valued at approximately $5,254,744.64. This trade represents a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 133,043 shares of company stock worth $4,977,158 over the last quarter. Insiders own 6.30% of the company’s stock.

Artivion Price Performance

Shares of AORT stock opened at $23.77 on Tuesday. The company has a market capitalization of $1.15 billion, a P/E ratio of 99.06 and a beta of 1.41. The company’s 50-day simple moving average is $36.01 and its two-hundred day simple moving average is $40.94. Artivion, Inc. has a one year low of $19.16 and a one year high of $48.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.15% and a net margin of 2.55%.The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. The company’s revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts anticipate that Artivion, Inc. will post 0.5 EPS for the current year.

Analysts Set New Price Targets

AORT has been the topic of a number of recent analyst reports. Citizens Jmp reduced their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Stifel Nicolaus set a $55.00 price objective on Artivion in a research report on Thursday, March 5th. Finally, LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.